Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514346 | PMC |
| http://dx.doi.org/10.1080/21645515.2015.1049091 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients.
Clin Cancer Res
December 2009
Authors' Affiliations: Department of Medical Oncology, National Cancer Centre, Singapore; DanDrit Biotech A/S, Copenhagen, Denmark; Singapore General Hospital, Singapore; and The Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
PURPOSE: We evaluated the clinical benefit of an allogeneic melanoma cell lysate (MCL)-pulsed autologous dendritic cell (DC) vaccine in advanced colorectal cancer patients expressing at least one of six MAGE-A antigens overexpressed by the cell line source of the lysate. EXPERIMENTAL DESIGN: DCs were cultured from peripheral blood mononuclear cells (PBMC), pulsed with the allogeneic MCL, and matured using cytokines that achieved high CD83- and CCR7-expressing DCs. Each patient received up to 10 intradermal vaccinations (3-5 x 10(6) cells per dose) at biweekly intervals.
View Article and Find Full Text PDFComparison of monocyte-derived dendritic cells from colorectal cancer patients, non-small-cell-lung-cancer patients and healthy donors.
Vaccine
December 2009
DanDrit Biotech A/S, Symbion Science Park, Copenhagen, Denmark.
Dendritic cells (DCs) are bone marrow-derived professional antigen presenting cells. Due to their role as potent inducers of immune responses, these cells are widely used as adjuvant in experimental clinical settings for cancer immune therapy. We have developed a DC-based vaccine using autologous blood monocytes loaded with allogeneic tumor cell lysate rich in cancer/testis antigens.
View Article and Find Full Text PDFFast generation of dendritic cells.
Cell Immunol
November 2009
Dandrit Biotech A/S, Symbion Science Park, Copenhagen, Denmark.
Dendritic cells (DC) are potent antigen presenting cells capable of inducing immune responses. DC are widely used as vaccine adjuvant in experimental clinical settings. DC-based vaccines are normally generated using a standard 8day DC protocol (SDDC).
View Article and Find Full Text PDFReal-time PCR analysis of genes encoding tumor antigens in esophageal tumors and a cancer vaccine.
Cancer Immun
October 2009
DanDrit Biotech A/S, Copenhagen, Denmark.
Tumor antigens are the primary target of therapeutic cancer vaccines. We set out to define and compare the expression pattern of tumor antigen genes in esophagus carcinoma biopsies and in an allogeneic tumor lysate-based cancer vaccine, MelCancerVac. Cells used for vaccine production were treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR) to determine whether this treatment could improve the profile of tumor antigen genes expressed in these cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!